Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A)

Anesthesiology

Volumn 116, Issue 2, 2012, Pages 432-447

  Kharasch, Evan D ^a   Bedynek, Pamela Sheffels ^b   Hoffer, Christine ^b   Walker, Alysa ^b   Whittington, Dale ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; CYTOCHROME P450 3A; FEXOFENADINE; GLYCOPROTEIN P; INDINAVIR; INTESTINE ENZYME; LIVER ENZYME; METHADONE; OPIATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG ELIMINATION; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; FIRST PASS EFFECT; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; LIVER CLEARANCE; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; METHYLATION; MIOSIS; NORMAL HUMAN; PRIORITY JOURNAL; TREATMENT DURATION;

ADOLESCENT; ADULT; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; HUMANS; INDINAVIR; INTESTINES; LIVER; MALE; METABOLIC CLEARANCE RATE; METHADONE; YOUNG ADULT;

EID: 84856428990     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3182423478     Document Type: Article

References (77)

1. Nicholson AB: Methadone for cancer pain. Cochrane Database Syst Rev 2007: CD003971
2. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O'Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C, American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10:113-30
3. Lobmaier P, Gossop M, Waal H, Bramness J: The pharmacological treatment of opioid addiction: A clinical perspective. Eur J Clin Pharmacol 2010; 66:537-45
4. Kharasch ED: Intraoperative methadone: Rediscovery, reappraisal, and reinvigoration? Anesth Analg 2011; 112:13-6
5. Clark JD: Understanding methadone metabolism: A foundation for safer use. Anesthesiology 2008; 108:351-2 (Pubitemid 351304225)
6. Sims SA, Snow LA, Porucznik CA: Surveillance of methadonerelated adverse drug events using multiple public health data sourcE.S. J Biomed Inform 2007; 40:382-9 (Pubitemid 47187788)
7. Ferrari A, Coccia C.P., Bertolini A, Sternieri E: Methadone-metabolism, pharmacokinetics and interactions. Pharmacol Res 2004; 50:551-9
8. McCance-Katz EF, Sullivan LE, Nallani S: Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. Am J Addict 2010; 19:4-16
9. Saber-Tehrani AS, Bruce RD, Altice FL: Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. Am J Drug Alcohol Abuse 2011; 37:1-11
10. de Vos JW, Geerlings PJ, van den Brink W, Ufkes JG, van Wilgenburg H: Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. Eur J Clin Pharmacol 1995; 48:361-6
11. Iribarne C, Berthou F, Baird S, Dréano Y, Picart D, Bail JP, Beaune P, Ménez JF: Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomE.S. Chem Res Toxicol 1996; 9:365-73 (Pubitemid 26079977)
12. Moody DE, Alburges ME, Parker RJ, Collins JM, Strong JM: The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Dispos 1997; 25:1347-53 (Pubitemid 28010919)
13. Eap CB, Buclin T, Baumann P: Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clin Pharmacokinet 2002; 41:1153-93 (Pubitemid 35398691)
14. Crettol S, Déglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hämmig R, Monnat M, Hüttemann H, Baumann P, Eap CB: Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005; 78:593-604 (Pubitemid 41773635)
15. Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, Eap CB: ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006; 80:668-81 (Pubitemid 44920225)
16. Shiran MR, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT, Rostami-Hodjegan A: Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol 2009; 67:29-37
17. Gruber VA, McCance-Katz EF: Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Curr HIV/AIDS Rep 2010; 7:152-60
18. Gerber JG, Rhodes RJ, Gal J: Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 2004; 16:36-44 (Pubitemid 37532283)
19. Kharasch ED, Hoffer C, Whittington D, Sheffels P: Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004; 76:250-69 (Pubitemid 39221799)
20. Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED: Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther 2007; 321:389-99 (Pubitemid 46456979)
21. Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED: Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008; 108:363-74 (Pubitemid 351304229)
22. Chang Y, Fang WB, Lin SN, Moody DE: Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: A reconciliation. Basic Clin Pharmacol Toxicol 2011; 108:55-62
23. Thompson SJ, Koszdin K, Bernards CM: Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 2000; 92:1392-9 (Pubitemid 30257201)
24. Bauer B, Yang X, Hartz AM, Olson ER, Zhao R, Kalvass JC, Pollack GM, Miller DS: In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol 2006; 70:1212-9 (Pubitemid 44435972)
25. Crettol S, Digon P, Golay KP, Brawand M, Eap CB: In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R,S)-methadone, LAAM and their main metabolitE.S. Pharmacology 2007; 80:304-11 (Pubitemid 47557265)
26. Ortega I, Rodriguez M, Suarez E, Perez-Ruixo JJ, Calvo R: Modeling methadone pharmacokinetics in rats in presence of P-glycoprotein inhibitor valspodar. Pharm Res 2007; 24: 1299-308 (Pubitemid 46870595)
27. Kharasch ED, Bedynek PS, Park S, Whittington D, Walker A, Hoffer C: Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin Pharmacol Ther 2008; 84:497-505
28. Kharasch ED, Bedynek PS, Walker A, Whittington D, Hoffer C: Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activitiE.S. Clin Pharmacol Ther 2008; 84:506-12
29. Kharasch ED, Walker A, Whittington D, Hoffer C, Bedynek PS: Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend 2009; 101:158-68
30. Kharasch ED, Hoffer C, Whittington D, Walker A, Bedynek PS: Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: Insights from methadone interactions with ritonavir/ indinavir. Anesthesiology 2009; 110:660-72
31. Kharasch ED, Walker A, Hoffer C, Sheffels P: Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther 2004; 76:452-66 (Pubitemid 39469869)
32. Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K, Whittington D, Ensign D: Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther 2007; 82:410-26 (Pubitemid 47414348)
33. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, Hall SD: The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 2003; 74: 275-87 (Pubitemid 37083103)
34. Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, Nettleton D: A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 2008; 36:1698-708
35. Fahmi OA, Ripp SL: Evaluation of models for predicting drug-drug interactions due to induction. Expert Opin Drug Metab Toxicol 2010; 6:1399-416
36. Rostami-Hodjegan A, Tucker G: In silico' simulations to assess the in vivo' consequences of in vitro' metabolic drug-drug interactions. Drug Discovery Today: Technologies 2004; 1:441-8 (Pubitemid 40186348)
37. Kirby BJ, Unadkat JD: Impact of ignoring extraction ratio when predicting drug-drug interactions, fraction metabolized, and intestinal first-pass contribution. Drug Metab Dispos 2010; 38:1926-33
38. Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, Unadkat JD: Complex drug interactions of HIV protease inhibitors 1: Inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab Dispos 2011; 39:1070-8
39. Galetin A, Gertz M, Houston JB: Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions. Drug Metab Pharmacokinet 2010; 25:28-47
40. Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH: Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 1996; 24:307-14 (Pubitemid 26087084)
41. Iribarne C, Berthou F, Carlhant D, Dreano Y, Picart D, Lohezic F, Riche C: Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 1998; 26:257-60 (Pubitemid 28182402)
42. Unadkat JD, Wang Y: Protease inhibitors, Metabolic Drug Interactions. Edited by Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M. Philadelphia, Lippincott, Williams & Wilkins, 2000, pp 647-52
43. Ernest CS II, Hall SD, Jones DR: Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 2005; 312:583-91 (Pubitemid 40189555)
44. Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT: Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 2006; 98:79-85
45. Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, Kharasch ED: Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab Dispos 1995; 23:490-6
46. Klees TM, Sheffels P, Dale O, Kharasch ED: Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymE.S. Drug Metab Dispos 2005; 33:303-11 (Pubitemid 40279928)
47. Burger D, Boyd M, Duncombe C, Felderhof M, Mahanontharit A, Ruxrungtham K, Ubolyam S, Stek M, Cooper D, Lange J, Phanupak P, Reiss P: Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother 2003; 51:1231-8 (Pubitemid 36622079)
48. Kraft WK, McCrea JB, Winchell GA, Carides A, Lowry R, Woolf EJ, Kusma SE, Deutsch PJ, Greenberg HE, Waldman SA: Indinavir and rifabutin drug interactions in healthy volunteers. J Clin Pharmacol 2004; 44:305-13 (Pubitemid 38233827)
49. Anderson PL, Brundage RC, Bushman L, Kakuda TN, Remmel RP, Fletcher CV: Indinavir plasma protein binding in HIV-1-infected adults. AIDS 2000; 14:2293-7
50. Kharasch ED, Whittington D, Ensign D, Hoffer C, Bedynek PS, Campbell S, Stubbert K, Crafford A, London A, Kim T: Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther: in press
51. Gertz M, Harrison A, Houston JB, Galetin A: Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 2010; 38:1147-58
52. Wang Y, Unadkat JD: Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomE.S. Biopharm Drug Dispos 1999; 20:341-6 (Pubitemid 30255397)
53. de Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW, Beijnen JH: Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 2003; 42:223-82 (Pubitemid 36308064)
54. Gass RJ, Gal J, Fogle PW, Detmar-Hanna D, Gerber JG: Neither dapsone hydroxylation nor cortisol 6beta-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors. Eur J Clin Pharmacol 1998; 54:741-7 (Pubitemid 29024208)
55. Eagling VA, Back DJ, Barry MG: Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997; 44:190-4 (Pubitemid 27327076)
56. Purkins L, Wood N, Kleinermans D, Love ER: No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. Br J Clin Pharmacol 2003; 56:62-8 (Pubitemid 37491736)
57. Tucker GT, Houston JB, Huang SM: Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Clin Pharmacol Ther 2001;70:103-14 (Pubitemid 32777761)
58. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999; 27:866-71 (Pubitemid 29347585)
59. Bailey DG, Dresser GK, Leake BF, Kim RB: Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther 2007; 81:495-502 (Pubitemid 46452308)
60. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 2001; 299:620-8 (Pubitemid 32979675)
61. Perloff MD, Störmer E, von Moltke LL, Greenblatt DJ: Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm Res 2003; 20:1177-83 (Pubitemid 36951842)
62. Swift B, Tian X, Brouwer KL: Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function. Pharm Res 2009; 26:1942-51
63. Maas B, Kerr T, Fairbairn N, Montaner J, Wood E: Pharma-cokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence. Expert Opin Drug Metab Toxicol 2006; 2:533-43 (Pubitemid 46118324)
64. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, Hyland R, Obach RS: Comparison of different algorithms for predicting clinical drugdrug interactions, based on the use of CYP3A4 in vitro data: Predictions of compounds as precipitants of interaction. Drug Metab Dispos 2009; 37:1658-66
65. Foster DJ, Somogyi AA, Bochner F: Methadone N-demethylation in human liver microsomes: Lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 1999; 47:403-12 (Pubitemid 29161273)
66. Wang JS, DeVane CL: Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)-and (S)-methadone in vitro. Drug Metab Dispos 2003; 31:742-7
67. Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F: Steady-state pharmacokinetics of (R)-and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol 2000; 50:427-40
68. Shinderman M, Maxwell S, Brawand-Amey M, Golay KP, Baumann P, Eap CB: Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone dosE.S. Drug Alcohol Depend 2003; 69:205-11 (Pubitemid 36259782)
69. Foster DJ, Somogyi AA, White JM, Bochner F: Population pharmacokinetics of (R)-, (S)-and rac-methadone in methadone maintenance patients. Br J Clin Pharmacol 2004; 57: 742-55 (Pubitemid 38748042)
70. De Fazio S, Gallelli L, De Siena A, De Sarro G, Scordo MG: Role of CYP3A5 in abnormal clearance of methadone. Ann Pharmacother 2008; 42:893-7 (Pubitemid 351778097)
71. Lu WJ, Bies R, Kamden LK, Desta Z, Flockhart DA: Methadone: A substrate and mechanism-based inhibitor of CYP19 (aromatase). Drug Metab Dispos 2010; 38:1308-13
72. Kharasch ED, Mitchell D, Coles R, Blanco R: Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother 2008; 52:1663-9 (Pubitemid 351614658)
73. Liu P, Foster G, LaBadie RR, Gutierrez MJ, Sharma A: Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J Clin Pharmacol 2008; 48:73-84 (Pubitemid 350292275)
74. Jeong S, Nguyen PD, Desta Z: Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: Major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother 2009; 53:541-51
75. Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, Laine K: Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 2005; 77:553-9 (Pubitemid 40824968)
76. Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA: ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 2006; 80:682-90 (Pubitemid 44920224)
77. Bachmeier CJ, Spitzenberger TJ, Elmquist WF, Miller DW: Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm Res 2005; 22:1259-68 (Pubitemid 41176029)